Table 3 Ongoing clinical trials investigating the administration of immune checkpoint inhibitor agents in patients with mPC
From: Novel therapies are changing treatment paradigms in metastatic prostate cancer
Mechanism | Agent | Concurrent administered agent (Clinicaltrials.gov identifier) | Clinicaltrials.gov identifier | Other ongoing trials (number of subjects) |
|---|---|---|---|---|
Anti-PD1 | Nivolumab | 1. Ipilimumab (followed by nivolumab maintenance therapy) | 1. NCT03570619-IMPACT | NCT03835533 (45) NCT03600350 (41) NCT02933255 (29) NCT02601014 (15) |
2. Rucaparib, docetaxel, or enzalutamide | 2. NCT03338790-Checkmate 9KD | |||
Pembrolizumab | 1. Docetaxel | 1. NCT03834506-KEYNOTE-921 | NCT02499835 (72) | |
2. Enzalutamide | 2. NCT03834493-KEYNOTE-641 | NCT04090528 (60) | ||
3. Olaparib | 3. NCT03834519-KEYLYNK-010 | NCT02325557 (51) | ||
4. (a) olaparib, (b) docetaxel + prednisone, (c) enzalutamide, (d) abiraterone + prednisone | 4. NCT02861573/KEYNOTE-365 | NCT03093428 (45) | ||
Anti-PDL1 | Atezolizumab | Enzalutamide | NCT03016312-IMbassador250 | NCT02655822 (336) |
Anti-PDL1 + anti-CTLA-4 | Durvalumab + tremelimumab | Tremelimumab (IV) | 1. NCT03204812 | NCT02484404 (384) |
2. Tremelimumab (vaccine) plus PolyICLC | 2. NCT02643303 | |||
Anti-CTLA4 | Ipilimumab | 1. ADT | 1. NCT01377389 | Â |
2. Abiraterone acetate + prednisone | 2. NCT01688492 |